Core Viewpoint - The legal opinion letter from Grandall Law Firm (Hangzhou) confirms that Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd.'s 2023 restricted stock incentive plan has met the necessary conditions for the second vesting period, and the adjustments and cancellations of certain restricted stocks are compliant with relevant laws and regulations [2][20]. Group 1: Approval and Authorization - The company has received approval for the 2023 restricted stock incentive plan, with independent directors expressing agreement and no objections raised during the public notice period [6][9]. - The company’s supervisory board has verified that the proposed incentive objects meet the legal and regulatory requirements [7][9]. Group 2: Vesting Details - The second vesting period for the restricted stocks is defined as the first trading day after 24 months from the grant date until the last trading day within 36 months from the grant date, with 30% of the total granted rights eligible for vesting [10][12]. - The vesting conditions require that the company has not received negative audit opinions or failed to meet legal profit distribution requirements in the past 36 months [10][11]. Group 3: Adjustments - The grant price of the restricted stocks has been adjusted from 15.13 CNY per share to 10.1643 CNY per share due to capital increases and cash dividends [18]. - The number of restricted stocks granted has been adjusted from 1,518,750 shares to 2,126,250 shares based on the same factors [18]. Group 4: Cancellations - A total of 71,890 shares of restricted stock have been rendered void due to the departure of three incentive objects, which disqualified them from the incentive plan [19]. - The cancellation of these shares is in accordance with the provisions of the incentive plan regarding the treatment of unvested stocks upon employee departure [19]. Group 5: Conclusion - The legal opinion concludes that all aspects of the vesting, adjustments, and cancellations are in compliance with the Company Law, Securities Law, and relevant regulations, and the company will continue to fulfill its disclosure obligations [20].

上海君澜律师事务所 关于 南通海星电子股份有限公司 调整行权价格、注销部分股票期权及行权相关事项 之 法律意见书 二〇二五年六月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于南通海星电子股份有限公司 调整行权价格、注销部分股票期权及行权相关事项之 法律意见书 致：南通海星电子股份有限公司 上海君澜律师事务所（以下简称"本所"）接受南通海星电子股份有限公司（以 下简称"公司"或"海星股份"）的委托，根据《上市公司股权激励管理办法》（以下 简称"《管理办法》"）《南通海星电子股份有限公司 2024 年股票期权激励计划》（以下 简称"《激励计划》"或"本次激励计划"）的规定，就海星股份本次激励计划调整行权 价格、注销部分股票期权及行权相关事项（以下合称"本次调整、注销及行权"）出具 本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法律业务管 理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具 日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用 原则，进行了充分的核查验证，保证本法律意见所认 ...

证券代码：603162 证券简称：海通发展 公告编号：2025-069 福建海通发展股份有限公司 关于 2024 年股票期权与限制性股票激励计划 首次授予第一个解除限售期解除限售暨上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为2,212,500股。 ? 本次股票上市流通日期为2025 年 7 月 3 日。 一、2024 年股票期权与限制性股票激励计划批准及实施情况 （一）已履行的相关审批程序和信息披露情况 第四次会议，审议通过《关于 <福建海通发展股份有限公司 ensp="ensp" 年股票期权与限="年股票期权 与限"> 制性股票激励计划（草案）>及其摘要的议案》《关于 <福建海通发展股份有限公> 司 2024 年股票期权与限制性股票激励计划实施考核管理办法>的议案》等议案。 公司监事会对本次股权激励计划相关事项进行核实并出具了相关核查意见。 职务在公司内部进行了公示，在公示期内，公司监事会未收到与本次 ...

证券代码：603115 证券简称：海星股份 公告编号：2025-022 南通海星电子股份有限公司 关于调整 2024 年股票期权激励计划行权价格及注销部 分股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南通海星电子股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开了 第五届董事会第九次会议、第四届监事会第十九次会议，会议审议通过了《关于 调整 2024 年股票期权激励计划行权价格及注销部分股票期权的议案》，现对有 关事项说明如下： 一、2024 年股票期权激励计划（以下简称"本激励计划"）已履行的决策 程序和信息披露情况 了《关于公司<2024 年股票期权激励计划（草案）>及其摘要的议案》《关于公 司<2024 年股票期权激励计划实施考核管理办法>的议案》《关于提请股东大会 授权董事会办理股权激励相关事宜的议案》以及《关于召开公司 2024 年第二次 临时股东大会的议案》，相关议案已经公司董事会薪酬与考核委员会审议通过。 同日，公司召开第四届监事会第十三次会议，审议通过了《关于公司<202 ...

证券代码：002088 证券简称：鲁阳节能 公告编号：2025-027 第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 山东鲁阳节能材料股份有限公司（以下简称"公司"）于 2025 年 5 月 22 日召开第十 一届董事会第十四次（临时）会议和第十一届监事会第十二次（临时）会议，审议通过 了《关于 2024 年限制性股票激励计划首次授予部分第一个解除限售期解除限售条件成 就的议案》 ，公司 2024 年限制性股票激励计划（以下简称"本激励计划"）首次授予部分 第一个解除限售期解除限售条件已经成就。根据《公司 2024 年限制性股票激励计划（草 案）》（以下简称"《激励计划（草案）》"）的规定和公司 2024 年第一次临时股东大会 的授权，公司办理了本激励计划首次授予部分第一个解除限售期解除限售股份上市流通 手续。现将相关事项说明如下： 一、本激励计划已履行的相关审批程序 了《关于 <公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草案="草案"> 及其摘要 的议案》 山 ...

证券代码：688262 证券简称：国芯科技 公告编号：2025-053 苏州国芯科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为71,649,273股。 ? 本次股票上市流通日期为2025 年 7 月 7 日。（因 2025 年 7 月 6 日为非交 易日，故顺延至下一交易日） 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2021 年 12 月 7 日出具的《关于同意苏州国芯 科技股份有限公司首次公开发行股票注册的批复》 （证监许可20213860 号）核准， 苏州国芯科技股份有限公司（以下简称"公司"、 "国芯科技"或"发行人"）首次 向社会公众公开发行人民币普通股（A 股）股票 60,000,000 股，并于 2022 年 1 月 其中有限售条件流通股合计 186,743,902 股，无限售条件流通股合计 53,256,098 股。 本次上市流通的限售股为公司首次公开发行的部分限售股 ...

Core Viewpoint - The announcement details the shareholding structure and the planned share reduction by major shareholders of Babbi Food Co., Ltd, indicating a strategic move to meet personal funding needs while adhering to prior commitments regarding shareholding stability [1][2][4]. Shareholder Holding Situation - As of the announcement date, major shareholders Tianjin Huiping Investment Management Partnership, Tianjin Zhongyin Investment Management Partnership, and Tianjin Babbi Investment Management Partnership hold 13,387,142 shares (5.5881%), 9,962,229 shares (4.1584%), and 9,263,529 shares (3.8668%) respectively, all acquired before the IPO [1][2][3]. Reduction Plan Details - Tianjin Huiping plans to reduce up to 180,909 shares (0.0755%), Tianjin Zhongyin up to 731,199 shares (0.3052%), and Tianjin Babbi up to 1,102,811 shares (0.4603%) through centralized bidding within three months starting from July 21, 2025 [1][3][4]. - The reduction is motivated by personal funding needs and will be adjusted if there are changes in the company's capital structure during the reduction period [1][3]. Compliance with Previous Commitments - The major shareholders have previously committed not to transfer or manage their shares for 36 months post-IPO, and the current reduction plan aligns with these commitments [4][5].

证券代码：603259 证券简称：药明康德 公告编号：临 2025-043 无锡药明康德新药开发股份有限公司 关于 2025 年第一次以集中竞价交易方式首次回购公司股份 暨股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/3/18 □用于转换公司可转债 □为维护公司价值及股东权益 | 累计已回购股数 | 302,500股 | | --- | --- | | 累计已回购股数占总股本比例 | 0.0105% | | 累计已回购金额 | 20,008,386.00元 | | 实际回购价格区间 | 65.54元/股~67.36元/股 | 一、 回购股份的基本情况 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 3 月 17 日召开第三届董事会第十七次会议暨 2024 年年度董事会，并于 2025 年 4 月 29 日 召开 2024 年年度股东大会，审议通过《关于 2025 年以集中竞价交易方式回购公 司 A 股股份的议案》，同意使用自有资金和自筹资金 ...

Core Viewpoint - The article outlines the share buyback programme authorized by the Ordinary General Meeting of Marie Brizard Wine & Spirits, detailing its objectives, terms, and conditions for the buyback of shares [1][3]. Group 1: Share Buyback Programme Details - The share buyback programme aims to promote liquidity in transactions, retain shares for future market use, cover employee stock options, facilitate the delivery of shares related to securities, and potentially cancel shares [5][6]. - The maximum number of shares that can be repurchased is 11,059,240, which represents 9.88% of the company's share capital, with a potential increase to 10% if treasury shares are sold or utilized [4][6]. - The maximum purchase price for the shares is set at €6, leading to a theoretical maximum expenditure of €67,193,892 if all shares are bought back at this price [5]. Group 2: Duration and Reporting - The buyback programme is scheduled to last for 18 months, concluding on 26 November 2026, with the company committed to informing the public of any significant changes during this period [7]. - The company currently holds 139,742 treasury shares, which is 0.12% of its total share capital of 111,989,823 shares [2]. Group 3: Company Overview - Marie Brizard Wine & Spirits is a wine and spirits group with a strong presence in Europe and the United States, known for its innovative spirit and a portfolio of well-established brands [9]. - The company is listed on Compartment B of Euronext Paris and is part of the EnterNext© PEA-PME 150 index [10].

Core Insights - Meta has hired influential OpenAI researcher Trapit Bansal to enhance its AI reasoning models within a new AI superintelligence unit [1][2] - Bansal was instrumental in developing OpenAI's reinforcement learning initiatives and is recognized as a foundational contributor to OpenAI's first AI reasoning model, o1 [2] - The addition of Bansal is expected to significantly boost Meta's AI superintelligence lab, which includes other notable leaders from the tech industry [3] Company Developments - Mark Zuckerberg has been actively recruiting for Meta's AI team, offering substantial compensation packages, reportedly around $100 million, to attract top talent [4] - The specific compensation details for Bansal's move to Meta remain undisclosed [4] - Currently, Meta does not have a publicly available AI reasoning model as part of its Llama family of open models [3]